MIA PaCa-2人胰腺癌细胞
文献支持

MIA PaCa-2人胰腺癌细胞

收藏
  • ¥1350
  • 中乔新舟已认证
  • 中国
  • ZQ0454
  • 2025年12月12日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 英文名

      MIA PaCa-2

    • 库存

      大量

    • 供应商

      中乔新舟

    • 细胞类型

      细胞系

    • 相关疾病

    • 物种来源

      human

    • 免疫类型

    • 细胞形态

      咨询销售

    • 运输方式

      T25瓶运输

    • 年限

      5-10年

    • 生长状态

      贴壁生长

    • 规格

      5 x 10^5 cells/vial

    产品名称

    MIA PaCa-2人胰腺癌细胞

    货号

    ZQ0454

    产品介绍

    MIA PaCa-2细胞系来源于一名65岁男性胰腺癌组织,是肿瘤研究领域不可或缺的资产。其被广泛用于胰腺导管腺癌(PDAC)的研究,这是一种众所周知的侵袭性和致死性癌症类型。该细胞系提供了反映PDAC细胞特征的实体瘤模型。该细胞系的关键属性之一是其遗传谱,其中包括KRAS和TP53等关键基因的突变,这些基因是胰腺癌患者观察到的遗传景观的象征。
    该细胞被广泛用来研究胰腺癌的各个方面发展,转移和抵抗治疗,也是评估化疗药物疗效的重要工具。此外,该细胞系是探索癌细胞存活和转移的关键信号通路的重要资源,包括MAPK、PI3K/AKT和Wnt通路。利用MIA PaCa-2细胞的研究也揭示了癌细胞与其微环境之间的动态相互作用。MIA PaCa-2强大的体外生长能力及其在异种移植模型中形成肿瘤的能力使其特别适合于检查癌症进展和肿瘤发生机制。综上所述,Mia Paca-2细胞系在胰腺癌研究中的广泛应用,仍然是全世界科学家的重要资源。
    据报道,该细胞系倍增时间约40小时,在软琼脂中的集落形成效率约19%。该细胞系对天冬酰胺酶敏感。

    【注意事项】:该细胞贴壁较慢,传代或复苏48小时后方可贴壁完全。该细胞正常情况下为贴壁细胞与圆形漂浮细胞同时存在。换液时需注意保留漂浮细胞,传代时需将贴壁细胞和漂浮细胞一同收集后再传代。

    种属

    性别/年龄

    男/65岁

    组织

    胰腺

    疾病

    胰腺导管腺癌

    细胞类型

    肿瘤细胞

    形态学

    带有漂浮圆形细胞的附着上皮

    生长方式

    贴壁

    倍增时间

    大约18~40小时 

    培养基和添加剂

    DMEM(品牌:中乔新舟  货号:ZQ-100)+10%FBS(品牌:中乔新舟  货号:ZQ0500)+1%P/S(中乔新舟  货号:CSP006)+2.5%马血清(中乔新舟 货号:ZQH500)+1% Sodium Pyruvate 100 mM Solution(中乔新舟  货号:CSP003)

    推荐完全培养基货号

    ZM0454

    生物安全等级

    BSL-1

    STR位点信息

    D5S818: 12,13
    D13S317: 12,13
    D7S820: 12,13
    D16S539: 10,13
    vWA: 15
    THO1: 9,10
    Amelogenin: X
    TPOX: 9
    CSF1PO: 10

    培养条件

    95%空气,5%二氧化碳;37℃

    抗原表达/受体表达

     ***

    基因表达

     ***

    保藏机构

    ATCC; CRL-1420 DSMZ; ACC-733 ECACC; 85062806 JCRB; JCRB0070

    供应限制

    仅供科研使用

     

    上海中乔新舟生物科技有限公司成立于2011年,历经十多年发展,主要专注于细胞生物学产品的研究和开发,专注于为药企、各类科研机构及CRO企业提供符合标准规范的细胞培养服务、细胞培养基、细胞检测试剂盒、细胞培养试剂,胎牛血清和细胞生物学技术服务等。

    公司一直致力于为高等院校、研究机构、医院、CRO及CDMO企业提供细胞培养完整解决方案,这些产品旨在满足细胞培养的多样需求,确保实验和研究的有效进行。引用中乔新舟(ZQXZBIO)产品和服务的文献超数千篇。

    MIA PaCa-2人胰腺癌细胞

    产品服务

    细胞资源:原代细胞、细胞株、干细胞、示踪细胞、耐药株细胞、永生化细胞等基因工程细胞。

    试剂产品:胎牛血清、完全培养基(适用于原代细胞及细胞株)、无血清培养基、基础培养基、细胞转染试剂、重组因子、胰酶和双抗等等细胞培养所有实验相关产品。

    技术服务:稳转株构建、原代细胞分离、特殊培养基定制服务、细胞检测等。

    MIA PaCa-2人胰腺癌细胞

    目前产品已经畅销国内30多个省市,与客户建立长期的合作伙伴关系,共同实现成功。全体员工将不懈努力,继续为科研人员提供优良的产品和服务,致力成为全球细胞培养领域的参与者。

    MIA PaCa-2人胰腺癌细胞

    企业愿景

    致力于成为国内细胞培养基产业的佼佼者,生物医药领域上游原材料的优良提供商。

    企业使命

    成长为专业细胞系及原代细胞培养供应商、专业细胞培养基及培养试剂生产商。

    企业荣誉

    MIA PaCa-2人胰腺癌细胞

    MIA PaCa-2人胰腺癌细胞

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    论文标题: NEAT1/miR-101-dependent Up-regulation of DNA-PKcs Enhances Malignant Behaviors of Pancreatic Ductal Adenocarcinoma Cells
    DOI: 10.7150/jca.58824
    发表时间: 2021-07-25
    期刊: Journal of Cancer
    影响因子: 4.207
    货号: ZQ0454
    产品名称: MIA PaCa-2 cells
     

     

    论文标题: Anillin is a prognostic factor and is correlated with genovariation in pancreatic cancer based on databases analysis
    DOI: 10.3892/ol.2020.12368
    发表时间: 2020-12-10
    期刊: Oncology Letters
    影响因子: 2.311
    货号: ZQ0454
    产品名称: MIA PaCa-2 cells
     

     

    论文标题: HOXB5 promotes proliferation, migration, and invasion of pancreatic cancer cell through the activation of the GSK3β/β-catenin pathway
    DOI: 10.1097/CAD.0000000000000948
    发表时间: 2020-09-01
    期刊: ANTI-CANCER DRUGS
    影响因子: 2.26
    货号: ZQ0454
    产品名称: MIA-PaCa-2 cells

     

     

     

    PubMed=1764370; DOI=10.1038/bjc.1991.467
    Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.
    Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.
    Br. J. Cancer 64:1076-1082(1991)

     

    PubMed=1630814
    Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D., Klein-Szanto A.J.P.
    Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
    Oncogene 7:1503-1511(1992)

     

    PubMed=7809022; DOI=10.1097/00006676-199409000-00018
    Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J., Thompson J.C.
    Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation.
    Pancreas 9:657-661(1994)

     

    PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x
    Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T., Imamura M., Hiai H., Fukumoto M.
    K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.
    Jpn. J. Cancer Res. 85:1005-1014(1994)

     

    PubMed=8026879; DOI=10.1002/ijc.2910580207
    Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
    Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
    Int. J. Cancer 58:185-191(1994)

     

    PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7
    Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G., Arnold R.
    Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma.
    Gastroenterology 106:1645-1651(1994)

     

    PubMed=21607521; DOI=10.3892/or.1.6.1223
    Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.
    Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.
    Oncol. Rep. 1:1223-1227(1994)

     

    PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
    Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
    Screening the p53 status of human cell lines using a yeast functional assay.
    Mol. Carcinog. 19:243-253(1997)

     

    PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4
    Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.
    Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
    Am. J. Pathol. 154:525-536(1999)

     

    PubMed=11115575; DOI=10.3892/or.8.1.89
    Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.
    Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
    Oncol. Rep. 8:89-92(2001)

     

    PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U
    Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P., Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.
    Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis.
    Int. J. Cancer 91:340-344(2001)

     

    PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
    Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
    Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
    Int. J. Cancer 91:350-358(2001)

     

    PubMed=11787853; DOI=10.1007/s004280100474
    Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.
    Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
    Virchows Arch. 439:798-802(2001)

     

    PubMed=12068308; DOI=10.1038/nature00766
    Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
    Mutations of the BRAF gene in human cancer.
    Nature 417:949-954(2002)

     

    PubMed=12692724; DOI=10.1007/s00428-003-0784-4
    Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.
    A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.
    Virchows Arch. 442:444-452(2003)

     

    PubMed=14695172
    Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.
    Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
    Cancer Res. 63:8614-8622(2003)

     

    PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521
    Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
    Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
    World J. Gastroenterol. 11:1521-1528(2005)

     

    PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721
    Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.
    Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
    Cancer Res. 66:7920-7928(2006)

     

    PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001
    Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.
    Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.
    Biologicals 35:195-202(2007)

     

    PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x
    Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A., Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H., Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F., Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.
    Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling.
    J. Cell. Mol. Med. 12:2823-2835(2008)

     

    PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x
    Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.
    Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
    Cancer Sci. 99:986-994(2008)

     

    PubMed=18575732; DOI=10.3892/or.20.1.155
    Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N., Yoshino S., Hazama S.
    Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Oncol. Rep. 20:155-163(2008)

     

     

    CLPUB00416

    Oberlin L.
    Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
    Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany

     

     

    PubMed=19077451; DOI=10.1159/000178871
    Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.
    Genome-wide analysis of pancreatic cancer using microarray-based techniques.
    Pancreatology 9:13-24(2009)

     

    PubMed=19188929; DOI=10.1038/tpj.2008.20
    Guo J., Anderson M.G., Tapang P., Palma J.P., Rodriguez L.E., Niquette A.L., Li J.-L., Bouska J.J., Wang G., Semizarov D., Albert D.H., Donawho C.K., Glaser K.B., Shah O.J.
    Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
    Pharmacogenomics J. 9:90-102(2009)

     

    PubMed=19904223; DOI=10.1097/MPA.0b013e3181bc44dd
    Xiao J., Lee W.-N.P., Zhao Y.-C., Cao R., Go V.L.-W., Recker R.R., Wang Q., Xiao G.G.-S.
    Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media.
    Pancreas 39:E17-E23(2010)

     

    PubMed=20164919; DOI=10.1038/nature08768
    Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
    Signatures of mutation and selection in the cancer genome.
    Nature 463:893-898(2010)

     

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
    Cancer Res. 70:2158-2164(2010)

     

    PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963
    Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J.
    Phenotype and genotype of pancreatic cancer cell lines.
    Pancreas 39:425-435(2010)

     

    PubMed=22460905; DOI=10.1038/nature11003
    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
    Nature 483:603-607(2012)

     

    PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
    Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
    Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
    Cancer Discov. 2:172-189(2012)

     

    DOI=10.4172/2324-9293.1000104
    Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R., Saeger H.-D.
    Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.
    Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013)

     

    PubMed=23386380; DOI=10.1002/jcb.24506
    Bose B., Shenoy P.S.
    Non insulin producing cell line, MIA PaCa-2 is rendered insulin producing in vitro via mesenchymal epithelial transition.
    J. Cell. Biochem. 114:1642-1652(2013)

     


     

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥600
    上海匹拓生物科技有限公司
    2025年12月17日询价
    ¥1200
    上海继和生物科技有限公司
    2025年09月16日询价
    询价
    上海雅吉生物科技有限公司
    2025年07月14日询价
    ¥1200
    上海觅拓生物科技有限公司
    2025年04月09日询价
    ¥1800
    蒂科(上海)生物科技有限公司
    2025年06月23日询价
    文献支持
    MIA PaCa-2人胰腺癌细胞
    ¥1350